December 2021 in “Acta Marisiensis” Insulin resistance increases the risk of developing type 2 diabetes and other health issues.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
2 citations
,
April 2023 in “Polymers” The study created 3D-printed pills that effectively release a hair loss treatment drug over 24 hours.
8 citations
,
January 2023 in “Indian Dermatology Online Journal” Baricitinib effectively treats certain skin conditions but may have serious side effects.
16 citations
,
March 2011 in “Pediatric diabetes” Metformin helps manage diabetes, PCOS, and weight in kids but needs more research for long-term safety.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
November 2024 in “Journal of Cosmetic Dermatology” Baricitinib is effective for severe alopecia areata but has some side effects.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
July 2024 in “Journal of Investigative Dermatology”
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
32 citations
,
January 2021 in “Molecules” Some Middle Eastern plants may help treat diabetes and could be alternatives to current drugs, but more research is needed.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
August 2013 in “Hospital Pharmacy” Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.
Ziziphus jujuba and Eclipta alba leaf extracts improve blood sugar levels and cognitive function in diabetic rats.
6 citations
,
January 2021 in “International Journal of Molecular Sciences” Finasteride-treated male rats' offspring had altered glucose metabolism, potentially increasing diabetes risk.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
10 citations
,
February 2017 in “Hormone Molecular Biology and Clinical Investigation” Metformin effectively improves metabolic symptoms in women with PCOS, while alfacalcidiol does not have a significant impact.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
January 2022 in “Drugs of Today”
Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
September 2015 in “Photodiagnosis and Photodynamic Therapy”
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
June 2026 in “Eurasian Journal of Medicine” Baricitinib effectively regrew hair in a woman with alopecia universalis after other treatments failed.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
December 2020 in “Forum Dermatologicum” Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.